Sign in

    Giang Nguyen

    Vice President in Equity Research at Citigroup Inc.

    Giang Nguyen is a Vice President in Equity Research at Citigroup, specializing in the MedTech and European healthcare sectors. She covers key medical technology companies across the Germany, UK, and US markets, maintaining an analyst success rate of 57% on TipRanks over the past year with an average return of -5.6% per rating. Giang began her career as a Summer Analyst at Citi in 2017, rapidly rising through roles including Graduate Analyst before advancing to Vice President in 2019. Holding a First-Class Honours degree in Economics from University College London, she combines strong academic credentials with deep market knowledge to drive strategic insights within her coverage universe.

    Giang Nguyen's questions to Fresenius Medical Care (FMS) leadership

    Giang Nguyen's questions to Fresenius Medical Care (FMS) leadership • Q4 2024

    Question

    Giang Nguyen from Citi inquired about the expected U.S. volume growth exit rate for 2025 and the ramp-up trajectory, and also asked for comments on other assets being assessed for potential divestiture.

    Answer

    CEO Helen Giza responded that the volume growth ramp-up and exit rate in 2025 depend on when elevated mortality normalizes, but the company expects momentum to build throughout the year, leading to a 2% growth rate in 2026. Regarding divestitures, Giza clarified that not all assets marked for assessment will be sold. She stated that the company likes some of these assets as they are part of the overall strategy, and a further update on the portfolio and growth opportunities will be provided at the June Capital Markets Day.

    Ask Fintool Equity Research AI

    Giang Nguyen's questions to KONINKLIJKE PHILIPS (PHG) leadership

    Giang Nguyen's questions to KONINKLIJKE PHILIPS (PHG) leadership • Q4 2024

    Question

    Giang Nguyen asked about the expected growth phasing for the remainder of the year and the company's confidence in its full-year guidance. She also questioned the implications for margins and whether they could remain in range even if the top line misses, due to cost savings.

    Answer

    CFO Charlotte Hanneman stated the outlook is realistic but that both sales growth and margin expansion are expected to be back-end loaded. This is due to the double-digit decline in China in the first half, royalty phasing, and a high comparison base. She noted that productivity savings are also back-end loaded, leading to an expected gradual improvement in both sales and EBITA margin throughout the year.

    Ask Fintool Equity Research AI

    Giang Nguyen's questions to SCHOTT Pharma AG & Co. KGaA/ADR (SHTPY) leadership

    Giang Nguyen's questions to SCHOTT Pharma AG & Co. KGaA/ADR (SHTPY) leadership • Q1 2025

    Question

    Giang Nguyen of Citigroup Inc. inquired about the margin building blocks for the second half of the year, considering the mix impact from new glass syringe volumes and the recovery in core vials.

    Answer

    CFO Dr. Almuth Steinkuhler explained that second-half margin expansion will be driven primarily by additional volumes. Key drivers include 100% HVS glass syringes from new capacity, sterile cartridges with attractive margins, and improved utilization in core vials as strong order intake translates to revenue, reducing underutilization costs.

    Ask Fintool Equity Research AI